New precision therapy trial aims to match salivary gland cancer patients with the right drug

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histopathologic diagnosis of salivary gland carcinoma * The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining. * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment; * Age 18 or older - no upper limit; * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures; ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions: ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation/operation; ⑩Ability to comply with research visit schedules and other programmatic requirements. Exclusion Criteria: * Known hypersensitivity or delayed anaphylaxis to any agents in this trial; * Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover; * Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ; * To study the occurrence of arterial/venous thrombosis events within 6 months before medication; * Major cardiovascular diseases; * Is suffering from uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.; * Is suffering from an active infection that requires systemic treatment; * History of active tuberculosis; ⑨ Positive human immunodeficiency virus (HIV) test result; ⑩ Patients with chronic hepatitis B or active hepatitis C. ⑪Conditions that the investigator believes will affect the safety or compliance of the drug therapy in this study ⑫Female/male who is pregnant or breastfeeding or who intends to give birth;